Toyama and Eisai withdraw Japanese iguratimod filing for RA
This article was originally published in Scrip
Executive Summary
Toyama Chemical and development partner Eisai have temporarily withdrawn a Japanese approval filing for the rheumatoid arthritis (RA) therapy iguratimod (T-614), citing a need for additional clinical studies.